ReP USP - Resultado da busca

Artigo de periodico
Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF) (2013)
McMurray, John J. V.; Anand, Inder S.; Diaz, Rafael; Maggioni, Aldo P.; O’Connor, Christopher; Pfeffer, Marc A.; Solomon, Scott D.; Tendera, Michal; Veldhuisen, Dirk J. van; Albizem, Moetaz; Cheng, Sunfa; Scarlata, Debra; Swedberg, Karl; Young, James B.; Simões, Marcus Vinícius
Source: European Journal of Heart Failure. Unidade: FMRP
Subjects: ANEMIA, CARDIOPATIAS, COMORBIDADE, IDOSOS, CAUSA DA MORTE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCMURRAY, John J. V. et al. Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). European Journal of Heart Failure, v. 15, n. 3, p. 334\2013341, 2013Tradução . . Disponível em: https://doi.org/10.1093/eurjhf/hfs204. Acesso em: 03 nov. 2024.
APA
McMurray, J. J. V., Anand, I. S., Diaz, R., Maggioni, A. P., O’Connor, C., Pfeffer, M. A., et al. (2013). Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). European Journal of Heart Failure, 15( 3), 334\2013341. doi:10.1093/eurjhf/hfs204
NLM
McMurray JJV, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Solomon SD, Tendera M, Veldhuisen DJ van, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB, Simões MV. Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF) [Internet]. European Journal of Heart Failure. 2013 ; 15( 3): 334\2013341.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1093/eurjhf/hfs204
Vancouver
McMurray JJV, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Solomon SD, Tendera M, Veldhuisen DJ van, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB, Simões MV. Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF) [Internet]. European Journal of Heart Failure. 2013 ; 15( 3): 334\2013341.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1093/eurjhf/hfs204
Artigo de periodico
Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience (2011)
Skali, Hicham; Parving, Hans-Henrik; Parfrey, Patrick S.; Burdmann, Emmanuel A.; Lewis, Eldrin F.; Ivanovich, Peter; Keithi-Reddy, Sai Ram; McGill, Janet B.; McMurray, John J. V.; Singh, Ajay K.; Solomon, Scott D.; Uno, Hajime; Pfeffer, Marc A.
Source: Circulation. Unidade: FM
Subjects: DOENÇA CRÔNICA, REGRESSÃO LOGÍSTICA, ANEMIA, ERITROPOIETINA, DIABETES MELLITUS, NEFROPATIAS, ACIDENTE VASCULAR CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SKALI, Hicham et al. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience. Circulation, v. 124, n. 25, p. 2903-2908, 2011Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.111.030411. Acesso em: 03 nov. 2024.
APA
Skali, H., Parving, H. -H., Parfrey, P. S., Burdmann, E. A., Lewis, E. F., Ivanovich, P., et al. (2011). Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience. Circulation, 124( 25), 2903-2908. doi:10.1161/CIRCULATIONAHA.111.030411
NLM
Skali H, Parving H-H, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJV, Singh AK, Solomon SD, Uno H, Pfeffer MA. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience [Internet]. Circulation. 2011 ; 124( 25): 2903-2908.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.111.030411
Vancouver
Skali H, Parving H-H, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJV, Singh AK, Solomon SD, Uno H, Pfeffer MA. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience [Internet]. Circulation. 2011 ; 124( 25): 2903-2908.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.111.030411
Artigo de periodico
Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction (2005)
White, Harvey D.; Aylward, Philip E. G.; Huang, Zhen; Dalby, Anthony; Weaver, Douglas; Barvik, Stale; Marin-Neto, José Antônio; Murin, Jan; Nordlander, Rolf O.; Gilst, Wiek H. van; Zannad, Faiez; McMurray, John J. V.; Califf, Robert M.; Pfeffer, Marc A.
Source: Circulation. Unidade: FMRP
Subjects: VELHICE, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WHITE, Harvey D. et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Circulation, v. 29, p. 3391-3399, 2005Tradução . . Acesso em: 03 nov. 2024.
APA
White, H. D., Aylward, P. E. G., Huang, Z., Dalby, A., Weaver, D., Barvik, S., et al. (2005). Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Circulation, 29, 3391-3399.
NLM
White HD, Aylward PEG, Huang Z, Dalby A, Weaver D, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, Gilst WH van, Zannad F, McMurray JJV, Califf RM, Pfeffer MA. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Circulation. 2005 ; 29 3391-3399.[citado 2024 nov. 03 ]
Vancouver
White HD, Aylward PEG, Huang Z, Dalby A, Weaver D, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, Gilst WH van, Zannad F, McMurray JJV, Califf RM, Pfeffer MA. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Circulation. 2005 ; 29 3391-3399.[citado 2024 nov. 03 ]
Artigo de periodico
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial (2004)
Lemos, James A.; Blazing, Michael A.; Wiviott, Stephen D.; Lewis, Eldrin F.; Fox, Keith A. A.; White, Harvey D.; Rouleau, Jean-Lucien; Pedersen, Terje; Gardner, Laura H.; Mukherjee, Robin; Ramsey, Karen E.; Palmisano, Joanne; Bilheimer, David W.; Pfeffer, Marc A.; Califf, Robert M.; Braunwald, Eugene; Marin-Neto, José Antônio
Source: JAMA. Unidade: FMRP
Assunto: CORONARIOPATIA (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEMOS, James A. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA, v. 292, n. 11, p. 1307-1316, 2004Tradução . . Acesso em: 03 nov. 2024.
APA
Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., et al. (2004). Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA, 292( 11), 1307-1316.
NLM
Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen T, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Marin-Neto JA. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292( 11): 1307-1316.[citado 2024 nov. 03 ]
Vancouver
Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen T, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Marin-Neto JA. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292( 11): 1307-1316.[citado 2024 nov. 03 ]
Trabalho de evento-resumo periodico
Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study (2004)
Sampson, Uchechukwu K.; Kenchaiah, Satish; Swedberg, k.; White, Harvey; Lokhnygina, Yuliya; Mareev, Viacheslav; Barvik, Stale; Francis, Gary S.; Marin Neto, José Antônio; Werf, Frans Van de; Rouleau, Jean-Lucien; Pfeffer, Marc A.; Solomon, Scott
Source: Circulation. Conference titles: Scientific Sessions. Unidade: FMRP
Assunto: INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAMPSON, Uchechukwu K. et al. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 03 nov. 2024. , 2004
APA
Sampson, U. K., Kenchaiah, S., Swedberg, k., White, H., Lokhnygina, Y., Mareev, V., et al. (2004). Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Sampson UK, Kenchaiah S, Swedberg k., White H, Lokhnygina Y, Mareev V, Barvik S, Francis GS, Marin Neto JA, Werf FV de, Rouleau J-L, Pfeffer MA, Solomon S. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. 2004 ; 110( 17): III-642.[citado 2024 nov. 03 ]
Vancouver
Sampson UK, Kenchaiah S, Swedberg k., White H, Lokhnygina Y, Mareev V, Barvik S, Francis GS, Marin Neto JA, Werf FV de, Rouleau J-L, Pfeffer MA, Solomon S. Modifiable risk factors for stroke in high-risk patients following acute myocardial infarction: insights from the Valiant study. Circulation. 2004 ; 110( 17): III-642.[citado 2024 nov. 03 ]
Artigo de periodico
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial (2004)
Blazing, Michael A.; Lemos, James A. de; White, Harvey; Fox, Keith A. A.; Verheugt, Freek W. A.; Ardissino, Diego; DiBattiste, Peter M.; Palmisano, Joanne; Bilheimer, David W.; Snapinn, Steven M.; Ramsey, Karen E.; Gardner, Laura H.; Hasselblad, Vic; Pfeffer, Marc A.; Lewis, Eldrin F.; Braunwald, Eugene; Califf, Robert M.; Marin-Neto, José Antônio
Source: JAMA. Unidade: FMRP
Subjects: INFARTO DO MIOCÁRDIO (TRATAMENTO), ISQUEMIA MIOCÁRDICA (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BLAZING, Michael A. et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA, 2004Tradução . . Acesso em: 03 nov. 2024.
APA
Blazing, M. A., Lemos, J. A. de, White, H., Fox, K. A. A., Verheugt, F. W. A., Ardissino, D., et al. (2004). Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA.
NLM
Blazing MA, Lemos JA de, White H, Fox KAA, Verheugt FWA, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, Marin-Neto JA. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA. 2004 ;[citado 2024 nov. 03 ]
Vancouver
Blazing MA, Lemos JA de, White H, Fox KAA, Verheugt FWA, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, Marin-Neto JA. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA. 2004 ;[citado 2024 nov. 03 ]
Artigo de periodico
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (2003)
Pfeffer, Marc A.; McMurray, John J. V.; Velazquez, Eric J.; Rouleau, Jean-Lucien; Kober, Lars; Maggioni, Aldo P.; Solomon, Scott D.; Swedberg, Karl; Van de Werf, Frans; White, Harvey; Leimberger, Jeffrey D.; Henis, Marc; Edwards, Susan; Zelenkofske, Steven; Sellers, Mary Ann; Califf, Robert M.; Marin-Neto, José Antônio
Source: New England Journal of Medicine. Unidade: FMRP
Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR), INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PFEFFER, Marc A. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, v. 349, p. 1893-1906, 2003Tradução . . Disponível em: https://doi.org/10.1016/j.accreview.2003.12.039. Acesso em: 03 nov. 2024.
APA
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J. -L., Kober, L., Maggioni, A. P., et al. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349, 1893-1906. doi:10.1016/j.accreview.2003.12.039
NLM
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Marin-Neto JA. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Internet]. New England Journal of Medicine. 2003 ; 349 1893-1906.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.accreview.2003.12.039
Vancouver
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Marin-Neto JA. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Internet]. New England Journal of Medicine. 2003 ; 349 1893-1906.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.accreview.2003.12.039
Artigo de periodico
Valsartan in acute myocardial infarction trial (valiant): rationale and design (2000)
Pfeffer, Marc A.; McMurray, John; Leizorovicz, Alain; Maggioni, Aldo P.; Rouleau, Jean-Lucien; Van de Werf, Frans; Henis, Marc; Neuhart, Eric; Gallo, Paul; Edwards, Susan; Sellers, Mary Ann; Velazquez, Eric; Califf, Robert; Marin-Neto, José Antônio (Organizador)
Source: American Heart Journal. Unidade: FMRP
Subjects: DOENÇAS CARDIOVASCULARES (EPIDEMIOLOGIA), CARDIOPATIAS, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PFEFFER, Marc A. et al. Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal, v. 140, n. 5, p. 727-734, 2000Tradução . . Acesso em: 03 nov. 2024.
APA
Pfeffer, M. A., McMurray, J., Leizorovicz, A., Maggioni, A. P., Rouleau, J. -L., Van de Werf, F., et al. (2000). Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal, 140( 5), 727-734.
NLM
Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau J-L, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal. 2000 ; 140( 5): 727-734.[citado 2024 nov. 03 ]
Vancouver
Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau J-L, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (valiant): rationale and design. American Heart Journal. 2000 ; 140( 5): 727-734.[citado 2024 nov. 03 ]

USP Schools

ReP

Filtros

Authors

Date published

Subjects

Indexado em

Non normalized affiliation